Table 4.
Outcomes 12 months (or last follow‐up) after PH diagnosis.
| Treated SAPH (n = 38) | Untreated SAPH (n = 20) | |
|---|---|---|
| Change in FEV1 (mL)* | +13 ± 146 | −257 ± 237 |
| Change in FVC (mL)* | +54 ± 229 | −357 ± 332 |
| Change in 6MWD (m) | −24.5 ± 80.1 | −32.9 ± 52.9 |
| Change in weight (kg) | −0.44 ± 5.5 | 0.95 ± 4.1 |
| Oxygen requirement (L/min) | 4.4 ± 3.4 | 5.4 ± 3.7 |
| Lung transplant recipient* | ||
| Yes, n (%) | 22 (57.9) | 4 (20.0) |
| No, n (%) | 16 (42.1) | 16 (80.0) |
| Death before transplant | ||
| Yes, n (%) | 13 (34.2) | 11 (55.0) |
| No, n (%) | 25 (65.8) | 9 (45.0) |
| Median time to death after PH diagnosis, months (IQR)* | 50 (30–70) | 24 (14–34) |
| Death or lung transplant within 12 months of PH diagnosis, n (%)** | 5 (13.1) | 7 (35.0) |
Note: Patients with SAPH who received PH treatment had stable FEV1 and mildly improved FVC, while those who did not receive PH treatment had a decrease in FEV1 and FVC after 12 months, or the last follow‐up before death or transplant. The values listed for oxygen requirement are the new oxygen requirement at the time of follow‐up, not the change in oxygen requirement from baseline.
Abbreviations: 6MWD, 6‐minute walk distance; FEV1, forced expiratory volume in 1 s; FVC, functional vital capacity; IQR, interquartile range; PH, pulmonary hypertension; SAPH, sarcoidosis‐associated pulmonary hypertension.
*
p < 0.01
**
p < 0.05.